We are currently able to prescribe Wegovy to patients that meet the NICE criteria:
BMI ≥35 and at least one weight related co-morbidity (e.g. non-diabetic hyperglycaemia, type 2 diabetes, hypertension, sleep apnoea, fatty liver etc)
Due to limited capacity, we are prioritising patients with highest clinical need (based on National guidance).
Please consider prescribing medications such as tirzepatide (Mounjaro) for patients who have uncontrolled type 2 diabetes and who would benefit from weight loss
If patients would consider taking part in research trials of new weight loss drugs, they can register their interest by contacting Getinvolved@SomersetFT.nhs.uk
